El-Shakankery KH, Kefas J, Palmer K, Houston A, Mukherjee U, Gao K, Tan W, Crusz SM, Flynn MJ, Ledermann JA, Lockley M, McCormack M, MacDonald N, Nicum S, Devlin MJ and Miller RE (2024). Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London. MDPI  Cancers  vol. 16, (21)  

Merry E, Kesmez RT, Yu T, Flynn M, Ledermann J, Lockley M, Macdonald N, McCormack M, Nicum S, Crusz S and Miller R (2024). A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population. BMJ  International Journal of Gynecological Cancer   

Oxley S, Ahmed S, Baxter K, Blake D, Braden V, Brincat MR, Bryan S, Dilley J, Dobbs S, Durden A, Gomes N, Johnston B, Kaushik S, Kokka F, Lockley M, Lowe-Zinola J, Manchanda R, McCormick A, Nott C, Owens GL, Pandya A, Prince J, Ryan N, Sideris M, Tanna S, Waters J, Zamesa N, Thomas M and Olaitan A (2024). Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer. Elsevier  International Journal of Gynecological Cancer  vol. 34, (11) 1768-1774.  

Sullivan SM, Stoneham S, Lockley M, Frazier AL, Billmire DF and Poynter JN (2024). Comparison of overall and patterns of care in patients with a malignant ovarian germ cell tumor by age in the United States: a National Cancer Database (2004–2016) analysis. BMJ  International Journal of Gynecological Cancer  vol. 34, (12)  

Manchanda R, Sun L, Wei X and legood R (2024). Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Jones and Barlett Publishers  Journal of the National Comprehensive Cancer Network : JNCCN   

Pashankar F, Murray MJ, Gell J, MacDonald N, Shamash J, Billmire DF, Klosterkemper L, Olson T, Hirsch MS, Lockley M, Stoneham S and Frazier AL (2024). Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. Elsevier  EClinicalMedicine  vol. 69,  

Nuttall Musson E, Miller RE, Mansour MR, Lockley M, Ledermann JA and Payne EM (2023). Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention. Springer Nature  Leukemia  vol. 38, (1) 215-218.  

Musson EN, Lockley M, Mansour MR, Miller RE, Lederman J and Payne E (2023). Identification, Monitoring and Reversibility of PARP Inhibitor Associated Clonal Haematopoiesis and Myelodysplastic Syndrome: A Case Series. American Society of Hematology  Blood  vol. 142, (Supplement 1)  

Wood GE, Bunting CP, Veli M, Arora R, Berney DM, Alifrangis C, MacDonald ND, Miller RE, Shamash J, Stoneham S and Lockley M (2023). Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy. Frontiers  Frontiers in Oncology  vol. 13,  

Travis LB, Feldman DR, Fung C, Poynter JN, Lockley M and Frazier AL (2023). Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship. American Society of Clinical Oncology (ASCO)  Journal of Clinical Oncology  vol. 42, (6) 696-706.  

Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Fierheller C, Kalra A, Sia J, Miller RE, Mills‐Baldock T, Crusz SM, Sun L, Evans O, Robbani S, Jenkins LA, Ahmed M, Kumar A, Quigley M, Lockley M, Faruqi A, Casey L, Brockbank E, Phadnis S, Trevisan G, Singh N, Legood R and Manchanda R (2023). Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. Wiley  BJOG An International Journal of Obstetrics & Gynaecology  vol. 131, (6) 848-857.  

Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana I-G, Reinius MAV, Giannone G, Lewsley L-A, Stobo J, McQueen J, Bryson G, Eldridge M, Macintyre G, Markowetz F, Brenton JD and McNeish IA (2023). Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Springer Nature  Nature Communications  vol. 14, (1)  

Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana I-G, Reinius MAV, Giannone G, Lewsley L-A, Stobo J, McQueen J, Bryson G, Eldridge M, Macintyre G, Markowetz F, Brenton JD and McNeish IA (2023). The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Springer Nature  Nature Communications  vol. 14, (1)  

Puttock EH, Tyler EJ, Manni M, Maniati E, Butterworth C, Burger Ramos M, Peerani E, Hirani P, Gauthier V, Liu Y, Maniscalco G, Rajeeve V, Cutillas P, Trevisan C, Pozzobon M, Lockley M, Rastrick J, Läubli H, White A and Pearce OMT (2023). Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis. Springer Nature  Nature Communications  vol. 14, (1)  

Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER, Lamnisos A, Balega J, Brady AF, Sharma A, Izatt L, Kulkarni A, Tripathi V, Solomons JS, Hayes K, Hanson H, Snape K, Side L, Skates S, McGuire A and Rosenthal AN (2022). The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2. BMJ  Journal of Medical Genetics  vol. 60, (5) 440-449.  

Fonseca A, Lobo J, Hazard FK, Gell J, Nicholls PK, Weiss RS, Klosterkemper L, Volchenboum SL, Nicholson JC, Frazier AL, Amatruda JF, Bagrodia A, Lockley M and Murray MJ (2022). Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. Springer Nature  British Journal of Cancer  vol. 127, (9) 1577-1583.  

Palmer KR, El-Shakankery KH, Kefas J, Gao K, Crusz S, Flynn M, Jonathan L, Lockley M, McCormack M, Macdonald N, Nicum S, Devlin M-J and Miller R (2022). 600P Ethnic and socio-economic status in ovarian cancer patients recruited to clinical trials. Elsevier  Annals of Oncology  vol. 33,  

Graham R, Stoneham S, Lockley M and MacDonald ND (2022). Letter to Editor in Response to: Controlled Aspiration of Large Paediatric Ovarian Cystic Tumors. Elsevier  Journal of Pediatric Surgery  vol. 58, (10)  

Hoare JI, Hockings H, Saxena J, Silva VL, Haughey MJ, Wood GE, Nicolini F, Mirza H, McNeish IA, Huang W, Maniati E, Graham TA and Lockley M (2022). A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. Elsevier  Gynecologic Oncology  vol. 167, (1) 96-106.  

Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L and Hirsch MS (2022). Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. Elsevier  European Journal of Cancer  vol. 173, 59-70.  

Hockings H, Lockley M, Graham T, Lakatos E and Huang W (2022). Abstract PR015: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer. American Association for Cancer Research (AACR)  Cancer Research  vol. 82, (10_Supplement) pr015-pr015.  

Hockings H, Lockley M, Graham T, Lakatos E and Huang W (2022). Abstract B001: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer. American Association for Cancer Research (AACR)  Cancer Research  vol. 82, (10_Supplement) b001-b001.  

Cheng Z, Mirza H, Ennis DP, Smith P, Gavarró LM, Sokota C, Giannone G, Goranova T, Bradley T, Piskorz A, Lockley M, Investigators FTB, Kaur B, Singh N, Tookman LA, Krell J, McDermott J, Macintyre G, Markowetz F, Brenton JD and McNeish IA (2022). The Genomic Landscape of Early-Stage Ovarian High-Grade Serous CarcinomaGenomics of Early-Stage Ovarian High-Grade Serous Carcinoma. American Association for Cancer Research (AACR)  Clinical Cancer Research  vol. 28, (13) of1-of12.  

Graham R, MacDonald ND, Lockley M, Miller R, Butler J, Murali K, Sarker S-J, Banerjee S, Stoneham S, Shamash J, Liberale V, Berney DM and Newton C (2022). Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. Elsevier  European Journal of Obstetrics & Gynecology and Reproductive Biology  vol. 271, 138-144.  

Hoare JI, Osmani B, O’Sullivan EA, Browne A, Campbell N, Metcalf S, Nicolini F, Saxena J, Martin SA and Lockley M (2022). Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy. Springer Nature  Communications Biology  vol. 5, (1)  

Philpott S, Raikou M, Manchanda R, Evans G, Edmondson R, Menon U, Ahmed M, Woodward E, Lamnisos A, Lockley M, Scott M, Singh N, Skates S, Mcguire A and Rosenthal A (2021). 423 Results of the avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance program for BRCA mutation-carriers. BMJ  International Journal of Gynecological Cancer  vol. 31, a373-a374.  

Oxley SG, Achampong YA, Sambandan N, Hughes DJ, Thomas M, Lockley M and Olaitan A (2021). Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study. Wiley  Acta Obstetricia Et Gynecologica Scandinavica  vol. 100, (11) 2091-2096.  

Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, Khouly FE, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R and Lockley M (2021). Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study. MDPI  Cancers  vol. 13, (17)  

Lakatos E, Hockings H, Mossner M, Huang W, Lockley M and Graham TA (2021). LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations. Elsevier  iScience  vol. 24, (8)  

Lockley M, Stoneham S, Shamash J, Pashankar F and Frazier L (2021). Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’. Elsevier  European Journal of Cancer  vol. 152, 255-256.  

Silva VL, Saxena J, Nicolini F, Hoare JI, Metcalf S, Martin SA and Lockley M (2021). Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer. Springer Nature  Cell Death & Disease  vol. 12, (4)  

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim H-S, Lee J-Y, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Network THCC and Singh N (2021). Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448. Elsevier  Gynecologic Oncology  vol. 161, (1) 328-329.  

Lakatos E, Hockings H, Mossner M, Huang W, Lockley M and Graham TA (2021). LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations. Cold Spring Harbor Laboratory   

Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ, Hall M, Gallardo-Rincón D, Lockley M, Essapen S, Summers J, Anand A, Zachariah A, Williams S, Jones R, Scatchard K, Walther A, Kim J-W, Sundar S, Jayson GC, Ledermann JA and Clamp AR (2020). Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Elsevier  The Lancet Oncology  vol. 22, (2) 277-288.  

Alifrangis C, Sharma A, Chowdhury S, Duncan S, Milic M, Gogbashian A, Agarwal S, Sahdev A, Wilson P, Harland S, Stoneham S, Lockley M, Rustin G, Oliver T, Berney D and Shamash J (2020). Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. Elsevier  European Journal of Cancer  vol. 164, 105-113.  

Shamash J, Ansell W, Alifrangis C, Thomas B, Wilson P, Stoneham S, Mazhar D, Warren A, Barrett T, Alexander S, Rudman S, Lockley M, Berney D and Sahdev A (2020). The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). Springer Nature  British Journal of Cancer  vol. 124, (2) 368-374.  

Hoare JI, Hockings H, Saxena J, Silva VL, Maniati E, Mirza HB, Huang W, Wood GE, Nicolini F, Graham TA, McNeish IA and Lockley M (2020). Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer. Cold Spring Harbor Laboratory   

Berney DM, Shamash J, Stoneham S and Lockley M (2020). Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Elsevier  European Journal of Cancer  vol. 130, 267-268.  

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim H-S, Lee J-Y, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Network THCC and Singh N (2020). Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448]. Elsevier  Gynecologic Oncology  vol. 157, (2) 558-559.  

Berney DM, Stoneham S, Arora R, Shamash J and Lockley M (2019). Ovarian germ cell tumour classification: views from the testis. Wiley  Histopathology  vol. 76, (1) 25-36.  

McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L and Lanceley A (2019). Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. BMJ  International Journal of Gynecological Cancer  vol. 30, (2) 221-226.  

Macintyre G, Goranova TE, Silva DD, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G and Nourse C (2019). Abstract AP09: COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA. American Association for Cancer Research (AACR)  Clinical Cancer Research  vol. 25, (22_Supplement) ap09-ap09.  

Heath O (2019). The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases. 

Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J and Lockley M (2019). GCT-30 Surgical management of ovarian germ cell tumours. Elsevier  European Urology Open Science  vol. 18, (4)  

Shamash J, Ansell W, Alifrangis C, Sahdev A, Thomas B, Wilson P, Mazhar D, Warren A, Barrett T, Alexander S, Stoneham S, Rudman S, O’Brien T, Lockley M and Berney D (2019). GCT-84 The impact of a supranetwork-multidisciplinary team (SMDT) on decision making in testicular cancers: A ten-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). Elsevier  European Urology Open Science  vol. 18, (4)  

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Aggarwal S and Bronger H (2019). Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology   

Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Ledermann J, Berney DM, Shamash J, Banerjee S, Stoneham S and Lockley M (2019). A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Elsevier  European Journal of Cancer  vol. 113, 19-27.  

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD and McNeish IA (2019). Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. Springer Nature  British Journal of Cancer  vol. 120, (8) 868-868.  

Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R, Gilks B and Singh N (2019). Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. BMJ  International Journal of Gynecological Cancer  vol. 29, (2)  

Lockley M, Stoneham SJ and Olson TA (2018). Ovarian cancer in adolescents and young adults. Wiley  Pediatric Blood & Cancer  vol. 66, (3)  

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G and Nourse C (2018). Copy number signatures and mutational processes in ovarian carcinoma. Springer Nature  Nature Genetics  vol. 50, (9) 1262-1270.  

Devlin M-J, Chandrasekaran D, Singh N, Ledermann JA, Lockley M, McCormack M, Wilkinson N, Miller R and Kristeleit RS (2018). Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease. American Society of Clinical Oncology (ASCO)  Journal of Clinical Oncology  vol. 36, (15_suppl) 5581-5581.  

Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T and Side L (2018). Mainstreamed genetic testing for women with ovarian cancer: first-year experience. BMJ  Journal of Medical Genetics  vol. 56, (3)  

Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ, Brockbank E, Faruqi A, Gilks CB and Singh N (2017). A comparison of p53 and WT1 immunohistochemical expression patterns in tubo‐ovarian high‐grade serous carcinoma before and after neoadjuvant chemotherapy. Wiley  Histopathology  vol. 71, (5) 736-742.  

Glasspool RM, Blagden SP, Lockley M, Paul J, Hopkins C, Thomson F, Brown J, Fernandes R, Douglas N, Pou C, Hanif A, Campbell C, Multani PS, Tucker T, McNeish IA and Evans TRJ (2017). A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours. American Society of Clinical Oncology (ASCO)  Journal of Clinical Oncology  vol. 35, (15_suppl) 2594-2594.  

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD and McNeish IA (2017). Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. Springer Nature  British Journal of Cancer  vol. 116, (10) 1294-1301.  

La Russa M, Kokka F, Lockley M and Brockbank E (2016). Haemorrhagic shock due to spontaneous splenic rupture in a patient subsequently diagnosed with advanced ovarian cancer. Taylor & Francis  J Obstet Gynaecol  vol. 37, (2) 268-270.  

Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden KH, Lockley M and McNeish IA (2016). CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. American Association for Cancer Research  Cancer Research   

Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH, Chakravarty P, Thompson R, Topping J, Cutillas PR, Lockley M, Serody JS, Capasso M and Balkwill FR (2016). A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases. American Association for Cancer Research  Clinical Cancer Research   

BALKWILL F, Anne Montfort and Oliver Pearce (2016). Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. American Association for Cancer Research  Clinical Cancer Research   

Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Lockley M and McNeish IA (2016). Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer. American Association for Cancer Research (AACR)  Clinical Cancer Research  vol. 22, (2_Supplement) b53-b53.  

Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M, Martin SA and McNeish IA (2016). RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. American Association for Cancer Research (AACR)  Molecular Cancer Research  vol. 14, (1) 44-55.  

Browne A, Tookman LA, Ingemarsdotter CK, Bouwman RD, Pirlo K, Wang Y, McNeish IA and Lockley M (2015). Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. American Association for Cancer Research (AACR)  Cancer Research  vol. 75, (14) 2811-2821.  

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB and Singh N (2015). Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. American Society of Clinical Oncology (ASCO)  Journal of Clinical Oncology  vol. 33, (22) 2457-2463.  

Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EYL, Dowson S, Webber L, Khan I, Ennis D, Syed N, Crook TR, Brenton JD, Lockley M and McNeish IA (2014). Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Wiley  Molecular Oncology  vol. 9, (4) 791-805.  

Spurrell EL and Lockley M (2014). Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience  vol. 8,  

Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T, Imhof BA, Balkwill FR and Nourshargh S (2013). Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB J  vol. 27, (10) 4244-4253.  

Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, Williams SL, Pirlo KJ, Willis AE, Lockley M and McNeish IA (2012). Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Mol Ther  vol. 20, (9) 1676-1688.  

Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S and Balkwill FR (2012). The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol  vol. 227, (2) 136-145.  

Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA and Carroll NR (2012). Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. PANCREATOLOGY  vol. 12, (1) 8-15.  

Connell CM, Shibata A, Tookman LA, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP and McNeish IA (2011). Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. J Clin Invest  vol. 121, (4) 1283-1297.  

Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR and McNeish IA (2011). Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Mol Ther  vol. 19, (3) 490-499.  

Connell CM, Shibata A, Tookman L, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP and McNeish IA (2011). Genomic DNA damage and ATR-Chk1 signalling determine adenovirus oncolytic efficacy in ovarian cancer. HUMAN GENE THERAPY  vol. 22, (10) A113-A113.  

Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP, Balkwill FR and McNeish IA (2010). p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Mol Cancer  vol. 9,  

Lolkema M, Lockley M, Zhou H, Duffner J, Kishomoto TK and Tuveson DA (2010). Abstract LB-43: M402, a novel heparin sulphate mimetic, synergizes with gemcitabine to improve survival and reduce metastasis and epithelial-to-mesenchymal transition (EMT) in a genetically engineered mouse model for pancreatic cancer. American Association for Cancer Research (AACR)  Cancer Research  vol. 70, (8_Supplement)  

Lockley M and Eisen T (2009). Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer. OMICS International  Journal of clinical practice  vol. 6, (1) 111-124.  

Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR and McNeish IA (2008). Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene  vol. 27, (22) 3081-3090.  

Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR and McNeish IA (2006). Quantifying the activity of adenoviral E1A CR2 deletion mutants using Renilla luciferase bioluminescence and 3 '-deoxy-3 '-[F-18] fluorothymidine positron emission tomography imaging. CANCER RES  vol. 66, (18) 9178-9185.  

Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N and McNeish I (2006). Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res  vol. 66, (2) 989-998.  

McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP and Lemoine NR (2005). Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res  vol. 302, (1) 69-82.